Hepatoblastoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Mahshid |
||
| Line 19: | Line 19: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
[[Category:Hepatology]] | |||
Latest revision as of 01:58, 27 November 2017
|
Hepatoblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatoblastoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatoblastoma secondary prevention |
|
Risk calculators and risk factors for Hepatoblastoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Effective measures for the secondary prevention of hepatoblastoma include use of abdominal ultrasound and alpha-fetoprotein levels in patients with Beckwith-Wiedemann syndrome or isolated hemihyperplasia.[1]
Hepatoblastoma secondary prevention
- To detect abdominal malignancies at an early stage, all children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia are screened regularly for multiple tumor types including hepatoblastoma by abdominal ultrasound.[1]
- Screening using alpha-fetoprotein levels has also helped in the early detection of hepatoblastoma in these children.[1]
References
- ↑ 1.0 1.1 1.2 Beckwith-Wiedemann syndrome and hemihyperplasia. National Cancer Institute (2015). http://www.cancer.gov/types/liver/hp/child-liver-treatment-pdq#link/_509_toc Accessed on November 4, 2015